Neurava

Neurava is a private, pre-revenue medical device startup developing a first-of-its-kind wearable monitoring system for drug-resistant epilepsy. Its core innovation is a dual-device platform that not only detects convulsive seizures but also continuously tracks cardiac, respiratory, and oxygenation signals to assess the broader risk of SUDEP, a fatal complication. Backed by over $2M in funding and strategic support from pharmaceutical leader UCB, the company is advancing its technology through user testing with the goal of enabling data-driven, at-home care management and life-saving interventions.

AI-powered integrated wearable platform comprising the A1 (seizure detection) and N1 (cardiac, respiratory, oxygenation monitoring) devices, connected via a mobile app and cloud-based physician portal for SUDEP risk stratification.

Competes against standalone seizure detection wearables (e.g., Embrace2) but is differentiated by integrated cardiorespiratory monitoring for SUDEP risk. Faces potential future competition from consumer tech companies enhancing health features in smartwatches and from other neurology-focused medtech entrants.